Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to evaluate different treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in genotype 3 HCV infected cirrhotic patients.

Next Previous
Trial Profile

Study to evaluate different treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in genotype 3 HCV infected cirrhotic patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms STEPS

Most Recent Events

  • 01 Jun 2012 Primary endpoint 'Sustained-virological-response-rate' has been met.
  • 01 Jun 2012 Status changed from active, no longer recruiting to completed.
  • 12 Apr 2012 New source identified and integrated (EudraCT2007-002743-24: European Clinical Trials Database).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top